MRNA
Moderna Inc.
Price performance
Sep 18, 2026About
Company activity
28 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 09/01 | MRNA | 8-K | Moderna Announces Private Placement of $3 Billion Convertible Senior Notes | — | — | — |
| 07/31 | MRNA | 8-K | Moderna Reports Q2 2026 Financial Results and Pipeline Updates | — | — | — |
| 07/08 | MRNA | 8-K | Moderna Appoints Michael McDonnell to Board of Directors | — | — | — |
| 05/11 | MRNA | 8-K | Moderna Updates By-Laws and Announces Annual Meeting Results | — | — | — |
| 05/01 | MRNA | 8-K | Moderna Reports First Quarter 2026 Financial Results and Business Updates | — | — | — |
| 03/04 | MRNA | 8-K | Moderna Settles Patent Infringement Litigation with Arbutus/Genevant | — | — | — |
| 02/13 | MRNA | 8-K | Moderna Reports Fourth Quarter 2025 Financial Results and Business Updates | — | — | — |
| 02/10 | MRNA | 8-K | Moderna's BLA for Seasonal Influenza Vaccine mRNA-1010 Refused by FDA | — | — | — |
| 01/12 | MRNA | 8-K | Moderna Updates 2025 Financial Performance and 2026 Outlook | — | — | — |
| 01/05 | MRNA | 8-K | Moderna Reports 2025 Performance and Outlines 2026 Outlook | — | — | — |
| 11/24/25 | MRNA | 8-K | Moderna, Inc. Announces New $1.5 Billion Credit Facility | — | — | — |
| 11/20/25 | MRNA | 8-K | Moderna Discloses Pipeline Progress and Business Strategy Updates | — | — | — |
| 11/13/25 | MRNA | 8-K | Moderna Approves One-Time Stock Option Exchange Program | — | — | — |
| 11/06/25 | MRNA | 8-K | Moderna, Inc. Announces Third Quarter 2025 Financial Results | — | — | — |
| 08/01/25 | MRNA | 8-K | Moderna Reports Second Quarter 2025 Financial Results and Business Updates | — | — | — |
| 05/05/25 | MRNA | 8-K | Moderna Stockholders Approve Key Proposals at 2025 Annual Meeting | — | — | — |
| 05/01/25 | MRNA | 8-K | Moderna Reports First Quarter 2025 Financial Results and Business Updates | — | — | — |
| 02/14/25 | MRNA | 8-K | Moderna Reports 2024 Financial Results and Provides 2025 Outlook | — | — | — |
| 01/13/25 | MRNA | 8-K | Moderna Reports Preliminary 2024 Financial Results and Provides 2025 Outlook | — | — | — |
| 11/07/24 | MRNA | 8-K | Moderna Reports Q3 2024 Financial Results and Business Updates | — | — | — |
| 10/02/24 | MRNA | 8-K | Moderna Appoints Abbas Hussain to Board of Directors | — | — | — |
| 09/12/24 | MRNA | 8-K | Moderna Announces R&D Updates and Financial Framework Extension | — | — | — |
| 08/01/24 | MRNA | 8-K | Moderna Reports Second Quarter 2024 Financial Results and Business Updates | — | — | — |
| 07/23/24 | MRNA | 8-K | Moderna Announces Board Changes with Appointment of David Rubenstein and Departures of Robert Langer and Stephen Berenson | — | — | — |
| 05/09/24 | MRNA | 8-K | Moderna, Inc. Approves Major Corporate Governance Amendments at Annual Meeting | — | — | — |
| 05/02/24 | MRNA | 8-K | Moderna Reports Q1 2024 Financial Results and Business Updates | — | — | — |
| 02/22/24 | MRNA | 8-K | Moderna Announces Fourth Quarter and Full Year 2023 Financial Results | — | — | — |
| 01/08/24 | MRNA | 8-K | Moderna Reports 2023 Financial Results and Provides Business Update | — | — | — |
MRNA filing record
Moderna Inc. (MRNA): 28 8-K filings summarized, the most recent on Sep 1, 2026.
What the 8-K filings said
- Sep 1, 2026 · medium impact
Moderna, Inc. has completed a private offering of $3,000,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2032. The notes are convertible into shares of Moderna's common stock under certain conditions and are subject to various events of default. The company intends to use the net proceeds for…
Moderna Announces Private Placement of $3 Billion Convertible Senior Notes - Jul 31, 2026 · high impact
Moderna, Inc. reported second quarter 2026 financial results with total revenue of $145 million, GAAP net loss of $(0.8) billion, and GAAP EPS of $(1.97). The company reiterated its plan for up to 10% revenue growth in 2026 and improved its 2026 operating expense outlook by approximately $0.2 billion. Moderna…
Moderna Reports Q2 2026 Financial Results and Pipeline Updates - Jul 8, 2026 · high impact
Moderna, Inc. announced on July 8, 2026, the appointment of Michael McDonnell to its Board of Directors, effective July 8, 2026. Mr. McDonnell, a seasoned financial executive with over 35 years of experience, most recently served as Chief Financial Officer of Biogen Inc. He will also serve on the Board's Audit…
Moderna Appoints Michael McDonnell to Board of Directors - May 11, 2026 · medium impact
On May 6, 2026, Moderna, Inc. announced several key governance and shareholder actions. The Board of Directors approved an amendment to the company's by-laws to designate federal district courts as the exclusive forum for securities-related complaints. Additionally, at the 2026 Annual Meeting of Stockholders…
Moderna Updates By-Laws and Announces Annual Meeting Results - May 1, 2026 · high impact
Moderna, Inc. reported its first quarter 2026 financial results, showing total revenue of $389 million, a GAAP net loss of $(1.3) billion, and GAAP EPS of $(3.40). The company reiterated its plan for up to 10% revenue growth and GAAP operating expense reductions in 2026. Moderna also provided updates on its pipeline…
Moderna Reports First Quarter 2026 Financial Results and Business Updates
SEC filings in the last five years
- 48 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K
- 2 Form 8-K/A